Cited by 111Thyroid Disorders and TreatmentsThyroid and Parathyroid SurgeryThyroid Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Hypothyroidism prevalence in the United States: a retrospective study combining National Health and Nutrition Examination Survey and claims data, 2009-2019.

Open access
Wyne, Kathleen L, Nair, Lekshmi, Schneiderman, Chris P, Pinsky, Brett, Antunez Flores, Oscar, Guo, Dianlin, Barger, Bruce, Tessnow, Alexander H·2022·Journal of the Endocrine Society

Abstract

Previous estimates determined prevalence of hypothyroidism (HT) to be 4.6% of the US population. This study aimed to update estimates of HT prevalence in the United States by retrospective analysis of 2 datasets. Data on HT type (overt or subclinical HT) and treatment were collected from the 2009-2010 and 2011-2012 National Health and Nutrition Examination Survey (NHANES) cycles. From the Optum administrative claims database, medical and pharmacy claims were collected between January 1, 2012, and December 31, 2019. Patients were defined as having HT if, per given year, they had >1 prescription for HT treatment, >1 claim indicating an HT diagnosis, or thyroid-stimulating hormone levels >4.0 mIU/L (NHANES arm). For both studies, treatment was defined as any evidence of synthetic or natural thyroid hormone replacement, identified by pharmacy claims or patient surveys. Data are reported as percentage of patients with HT and treatments received. Between 2009 and 2012, HT prevalence remained around 9.6% of the US population. The administrative claims dataset showed that HT prevalence grew from 9.5% in 2012 to 11.7% in 2019 and that >78% of patients received thyroxine (T4) monotherapy. Similarly, the NHANES dataset showed that T4 replacement therapy was the most common treatment for HT. From 2012-2019, patients with untreated HT grew from 11.8% to 14.4%. The prevalence of HT in the United States has steadily increased since 2009. Likewise, the percentage of hypothyroid-diagnosed patients not receiving treatment also increased, suggesting that the increased prevalence may be due to increased cases of subclinical HT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jendso/bvac172

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Proportion of patients with hypothyroidism from 2009 to 2012: Estimates from the National Health and Nutrition Examination Survey 2009-2010 and 2011-2012 survey results. Abbreviations: HT, hypothyroidism; RX, prescription.
Figure 1. Proportion of patients with hypothyroidism from 2009 to 2012: Estimates from the National Health and Nutrition Examination Survey 2009-2010 and 2011-2012 survey results. Abbreviations: HT, hypothyroidism; RX, prescription.CC BY-NC-ND · PubMed Central
Figure 2. Proportion of patients with hypothyroidism from 2012 to 2019: Estimates from the Optum administrative claims database.
Figure 2. Proportion of patients with hypothyroidism from 2012 to 2019: Estimates from the Optum administrative claims database.CC BY-NC-ND · PubMed Central
Figure 3. Proportion of patients with hypothyroidism by age from 2012 to 2019: Estimates from the Optum administrative claims database.
Figure 3. Proportion of patients with hypothyroidism by age from 2012 to 2019: Estimates from the Optum administrative claims database.CC BY-NC-ND · PubMed Central
Figure 4. Proportion of patients with hypothyroidism in the United States by geographic region from 2012 to 2019: Estimates from the Optum administrative claims database.
Figure 4. Proportion of patients with hypothyroidism in the United States by geographic region from 2012 to 2019: Estimates from the Optum administrative claims database.CC BY-NC-ND · PubMed Central
Figure 5. Proportion of hypothyroid drugs used by class from 2012 to 2019: Estimates from the Optum administrative claims database. *Patients had a fill for both a T3 therapy and a separate T4 therapy within the same year. Abbreviations: T3, triiodothyronine; T4, thyroxine.
Figure 5. Proportion of hypothyroid drugs used by class from 2012 to 2019: Estimates from the Optum administrative claims database. *Patients had a fill for both a T3 therapy and a separate T4 therapy within the same year. Abbreviations: T3, triiodothyronine; T4, thyroxine.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 2

  1. [3]Patil N, Rehman A, Jialal I. Hypothyroidism. Accessed August 4, 2021. https://www.ncbi.nlm.nih.gov/books/NBK519536/
  2. [9]National Institute for Healthcare and Excellence. Thyroid disease: assessment and management. NICE Guideline. 2019. 31829541

Cited by

Sorted by citations

See all 111

Metadata

Authors
Wyne, K. L., Nair, L., Schneiderman, C. P., Pinsky, B., Antunez Flores, O., Guo, D., Barger, B., & Tessnow, A. H.
Affiliations
  • The Ohio State University Wexner Medical Center (US)
  • AbbVie (United States) (US)
  • AbbVie, Inc. , Chicago, IL , USA
  • Division of Endocrinology, Diabetes, and Metabolism, University of Texas Southwestern Medical Center , Dallas, TX , USA
Venue
Journal of the Endocrine Society
Published
2022-11-10
Volume
7
Issue
1
Pages
bvac172-bvac172
ISSN
2472-1972 (ISSN-L)
OpenAlex
W4308881891
Cited by
111
References
28
Citations by year
2026: 28 · 2025: 34 · 2024: 34 · 2023: 15
FWCI
15.38
Type
journal article
Language
en
Open access
Locations
  • Journal of the Endocrine Society (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
AbbVie
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Keywords
hypothyroidism, prevalence, subclinical hypothyroidism, overt hypothyroidism, thyroid hormone replacement, levothyroxine monotherapy, untreated hypothyroidism, thyroid-stimulating hormone, United States

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review